Cargando…

Correction: Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters on Chromosome 5q31 in Wilms' Tumor

Detalles Bibliográficos
Autores principales:	Dallosso, Anthony R., Hancock, Anne L., Szemes, Marianna, Moorwood, Kim, Chilukamarri, Laxmi, Tsai, Hsin-Hao, Sarkar, Abby, Barasch, Jonathan, Vuononvirta, Raisa, Jones, Chris, Pritchard-Jones, Kathy, Royer-Pokora, Brigitte, Lee, Sean Bong, Owen, Ceris, Malik, Sally, Feng, Yi, Frank, Marcus, Ward, Andrew, Brown, Keith W., Malik, Karim
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791684/ http://dx.doi.org/10.1371/annotation/012d5a44-8239-4057-8c3b-3dc159ea3a02

Ejemplares similares

Frequent Long-Range Epigenetic Silencing of Protocadherin Gene Clusters on Chromosome 5q31 in Wilms' Tumor
por: Dallosso, Anthony R., et al.
Publicado: (2009)

The yin and yang of kidney development and Wilms’ tumors
por: Hohenstein, Peter, et al.
Publicado: (2015)

Bilateral Wilms tumour: a review of clinical and molecular features
por: Charlton, Jocelyn, et al.
Publicado: (2017)

The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor
por: Legge, Danny, et al.
Publicado: (2021)

Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma
por: He, Ya, et al.
Publicado: (2019)

Chemotherapy and terminal skeletal muscle differentiation in WT1‐mutant Wilms tumors
por: Royer‐Pokora, Brigitte, et al.
Publicado: (2018)

Protocadherin 17 Is a Tumor Suppressor and Is Frequently Methylated in Nasopharyngeal Carcinoma [Retraction]
Publicado: (2020)

Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2
por: Rapley, E A, et al.
Publicado: (2000)

Evidence for a delay in diagnosis of Wilms’ tumour in the UK compared with Germany: implications for primary care for children
por: Pritchard-Jones, Kathy, et al.
Publicado: (2016)

Gene expression studies of WT1 mutant Wilms tumor cell lines in the frame work of published kidney development data reveals their early kidney stem cell origin
por: Royer-Pokora, Brigitte, et al.
Publicado: (2023)

Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations
por: Royer-Pokora, Brigitte, et al.
Publicado: (2020)

Transcriptomic Analyses of MYCN-Regulated Genes in Anaplastic Wilms’ Tumour Cell Lines Reveals Oncogenic Pathways and Potential Therapeutic Vulnerabilities
por: Szemes, Marianna, et al.
Publicado: (2021)

miRNA Profiles as a Predictor of Chemoresponsiveness in Wilms’ Tumor Blastema
por: Watson, Jenny A., et al.
Publicado: (2013)

Multiple mechanisms of MYCN dysregulation in Wilms tumour
por: Williams, Richard D., et al.
Publicado: (2015)

Protocadherins bring cells together
por: Leslie, Mitch
Publicado: (2011)

Protocadherins at the Crossroad of Signaling Pathways
por: Pancho, Anna, et al.
Publicado: (2020)

The clinical impact of observer variability in lung nodule classification in children with Wilms tumour
por: Brok, Jesper Sune, et al.
Publicado: (2022)

Sequencing and comparative analysis of fugu protocadherin clusters reveal diversity of protocadherin genes among teleosts
por: Yu, Wei-Ping, et al.
Publicado: (2007)

Lin28 sustains early renal progenitors and induces Wilms tumor
por: Urbach, Achia, et al.
Publicado: (2014)

The IGF signalling pathway in Wilms tumours - A report from the ENCCA Renal Tumours Biology-driven drug development workshop
por: Maschietto, Mariana, et al.
Publicado: (2014)

The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study
por: Mitchell, C, et al.
Publicado: (2000)

Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood
por: Charlton, Jocelyn, et al.
Publicado: (2014)

Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation
por: Busch, Maike, et al.
Publicado: (2014)

Clustered protocadherins methylation alterations in cancer
por: Vega-Benedetti, Ana Florencia, et al.
Publicado: (2019)

Stratification of Wilms tumor by genetic and epigenetic analysis
por: Scott, Richard H., et al.
Publicado: (2012)

Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer
por: Yin, Xuedong, et al.
Publicado: (2016)

TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
por: Maschietto, Mariana, et al.
Publicado: (2014)

Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors()()
por: Treger, Taryn D., et al.
Publicado: (2018)

Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications
por: Cresswell, George D., et al.
Publicado: (2016)

The UMBRELLA SIOP–RTSG 2016 Wilms tumour pathology and molecular biology protocol
por: Vujanić, Gordan M., et al.
Publicado: (2018)

Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour
por: Charlton, Jocelyn, et al.
Publicado: (2015)

γ-Protocadherin structural diversity and functional implications
por: Goodman, Kerry Marie, et al.
Publicado: (2016)

Expression of protocadherin-20 in mouse taste buds
por: Hirose, Fumie, et al.
Publicado: (2020)

Wiring the Brain by Clustered Protocadherin Neural Codes
por: Wu, Qiang, et al.
Publicado: (2020)

Loss of heterozygosity at 7p in Wilms' tumour development
por: Powlesland, R M, et al.
Publicado: (2000)

Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15
por: Brandt, Artur, et al.
Publicado: (2016)

Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour.
por: Grundy, R. G., et al.
Publicado: (1998)

Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour
por: Hanks, Sandra, et al.
Publicado: (2014)

Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma
por: Bellamy, Jacob, et al.
Publicado: (2020)

Publisher Correction: The UMBRELLA SIOP–RTSG 2016 Wilms tumour pathology and molecular biology protocol
por: Vujanić, Gordan M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ptqpjp489t3qfl6a9be6vdh1ue